About: COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2
Creator	James, Andrew Bond, Richard Carpenter, Alexander Chambers, Owen Hancox, Jules Hanington, Oliver Harchi, Aziza Harmer, Stephen Sorgente, Antonio Stahel, Hendrik
Source	Medline; PMC; WHO
abstract	The COVID-19 pandemic is an unprecedented challenge and will require novel therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due to underlying comorbidities, polypharmacy and the disease process. Importantly, a number of the medications likely to receive significant use can themselves, particularly in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is primarily caused by inhibition of the hERG potassium channel either directly and/or by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may have a synergistic rather than additive effect which, in addition to any pre-existing polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed decisions regarding appropriate therapeutics and monitoring to keep our patients safe.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.3389/fcvm.2020.00085
bibo:pmid	32432127
has license	cc-by
sha1sum (hex)	bf0bcb59bff09c54fba54b797e0effc1d52391c9
schema:url	https://doi.org/10.3389/fcvm.2020.00085
resource representing a document's title	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2
has PubMed Central identifier	PMC7214683
has PubMed identifier	32432127
schema:publication	Front Cardiovasc Med
resource representing a document's body	covid:bf0bcb59bff09c54fba54b797e0effc1d52391c9#body_text
is schema:about of	named entity 'arrhythmia' named entity 'Torsades de Pointes' named entity 'drugs' named entity 'Arrhythmia' named entity 'MINI' named entity 'STRATEGIES' named entity 'MAY HAVE' named entity 'TRAFFICKING' named entity 'SAFE' named entity 'POLYPHARMACY' named entity 'OUR' named entity 'IMPAIRED' named entity 'CONCURRENT' named entity 'RISK OF' named entity 'ADDITIVE' named entity 'PRO-' named entity 'RECEIVE' named entity 'disease' named entity 'risk' named entity 'multiple' named entity 'therapeutic' named entity 'Knowledge' named entity 'SARS-CoV-2' named entity 'Challenges' named entity 'Patients' named entity 'hERG' named entity 'polypharmacy' named entity 'additive effect' named entity 'polypharmacy' named entity 'Torsades de Pointes' named entity 'SARS-CoV-2' named entity 'pathophysiological' named entity 'QTc' named entity 'systemic inflammatory response' named entity 'fulminant' named entity 'clinical trials' named entity 'delayed rectifier' named entity 'corrected QT interval' named entity 'QT prolongation' named entity 'EudraCT' named entity 'remdesivir' named entity 'synergistic' named entity 'haemodynamic' named entity 'pharmacological' named entity 'COVID-19' named entity 'ECG' named entity 'ceftriaxone' named entity 'SARS-CoV-2' named entity 'Torsades de Pointes' named entity 'COVID-19' named entity 'hypertension' named entity 'arrhythmia' named entity 'ACE2' named entity 'QT prolongation' named entity 'cardiomyopathy' named entity 'QT-prolonging medication' named entity 'polypharmacy' named entity 'prolonged QT interval' named entity 'hERG' named entity 'HRS' named entity 'QT prolongation' named entity 'antiviral agents' named entity 'macrolides' named entity 'COVID-19' named entity 'anti-malarial' named entity 'hERG' named entity 'antiviral agents' named entity 'co-morbidities' named entity 'COVID-19' named entity 'lopinavir/ritonavir' named entity 'TdP' named entity 'SARS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software